Rithim Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Rithim Biologics is a private, preclinical-stage biotech developing a novel platform for cardiac arrhythmia treatment. The company's strategy integrates a proprietary surgical delivery catheter, the DAAViS™, with targeted gene therapies designed to prevent tachyarrhythmias. Led by a co-founding team with deep expertise in cardiac electrophysiology and medical device commercialization, the company has secured an NIH grant and its first US patent. Rithim operates in the high-potential but competitive fields of gene therapy and cardiac electrophysiology, targeting a significant unmet need for durable, non-ablative treatments.

CardiovascularCardiac Arrhythmias

Technology Platform

Integrated platform combining a proprietary catheter (DAAViS™) for precise cardiac delivery with targeted gene therapies designed to prevent tachyarrhythmias.

Opportunities

The large, growing market for cardiac arrhythmia treatments presents a multi-billion-dollar opportunity, especially for a durable, one-time therapy that addresses the high recurrence rates of current standards like ablation.

The platform potential of the DAAViS™ catheter could extend beyond gene therapy to deliver other biologics, creating additional revenue streams.

Risk Factors

High scientific risk associated with pioneering cardiac gene therapy, including challenges in delivery, efficacy, and safety.

The company faces significant regulatory uncertainty and will require substantial capital to navigate costly clinical development in a competitive landscape dominated by large device and pharma companies.

Competitive Landscape

Rithim competes with large medical device companies (e.g., Abbott, Medtronic, Boston Scientific) offering advanced ablation technologies, and with pharmaceutical companies developing new anti-arrhythmic drugs. It also faces competition from other biotech firms exploring gene therapy, cell therapy, or neuromodulation for cardiovascular diseases.

More companies in Cell & Gene Therapy →More companies in United States →